INS and type 2 diabetes mellitus: A pooled analysis comparing the effects of SGLT2i and DPP4i use among T2DM patients with suboptimal sugar control with insulin injection also found that SGLT2i achieved greater reduction of HbA1C (−0.24%, 95% CI: −0.43 to 0.05%) compared to that observed with DPP4i (Min et al., 2017).